Study at a glance
Can vitamin D influence how the body handles iron?
Yes. Vitamin D can affect hepcidin, a hormone that restricts iron release into the blood. Laboratory work and small human studies support this pathway.
Does lowering hepcidin prove that vitamin D treats anaemia?
No. Anaemia involves too little haemoglobin, the oxygen-carrying protein in red blood cells. Lowering an iron-regulating hormone does not necessarily correct depleted iron stores or other causes of anaemia.
What happened in the longer trial in older adults?
Vitamin D supplementation raised vitamin D levels, but did not significantly improve the measured iron markers after a year. This limits claims that the mechanism produces a general iron benefit.
Why do inflammation and kidney disease matter?
Both can affect iron handling and red-cell production. They can change what blood markers mean and whether a change in vitamin D is likely to influence the wider problem.
Read the full article below ↓Vitamin D has a genuine mechanistic relationship with iron physiology, but the human evidence does not support a simple claim that higher vitamin D automatically improves iron status or corrects anaemia. The strongest mechanistic evidence concerns hepcidin, the hormone that limits ferroportin-mediated iron export. Vitamin D receptor signalling can suppress the hepcidin gene, and short human intervention studies show rapid reductions in circulating hepcidin. Yet longer randomized trials in older adults and chronic kidney disease often show little or no overall improvement in ferritin, transferrin saturation, serum iron or haemoglobin. The complete evidence therefore describes a regulated, context-dependent pathway rather than a universal treatment effect.
The mechanistic foundation is the hepcidin-ferroportin axis
Hepcidin reduces cellular iron export by targeting ferroportin. This limits intestinal iron transfer and macrophage recycling. Experimental vitamin D work shows direct suppression of HAMP transcription and corresponding increases in ferroportin protein.
The detailed mechanism and human high-dose evidence are examined in Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Full Study.
Human hepcidin responses can occur rapidly
A small human study found an approximately 34% reduction in circulating hepcidin within 24 hours of a large vitamin D dose. A subsequent randomized placebo-controlled trial found an approximately 73% reduction from baseline after one week in vitamin-D-treated healthy adults.
These observations support a physiologically active pathway, but ferritin and measured inflammatory cytokines did not change in the randomized healthy-adult trial. The evidence therefore already separates hepcidin regulation from whole-body correction of iron stores or inflammation.
Inflammation creates another route to iron restriction
Inflammatory signalling can raise hepcidin and retain iron within cells. This contributes to anaemia of inflammation and complicates interpretation of ferritin because ferritin itself can rise as an acute-phase reactant.
Inflammatory-bowel-disease studies link vitamin D insufficiency with higher hepcidin and lower haemoglobin, while short prospective treatment data show large falls in hepcidin and inflammatory markers as vitamin D status rises and disease activity changes. These data are examined in Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Full Study.
Inflammatory improvement makes ferritin particularly difficult to read
A fall in ferritin can indicate declining iron stores, but during resolution of inflammation it can also reflect a reduced acute-phase response. The interpretation therefore depends on transferrin saturation, serum iron, soluble transferrin receptor, haemoglobin and inflammatory markers rather than ferritin alone.
This is why the vitamin D and iron relationship cannot be reduced to one blood test. Both vitamin D biomarkers and iron biomarkers describe only parts of moving physiological systems.
Long-term randomized evidence limits the clinical claim
BEST-D provides a particularly important counterweight to the short hepcidin studies. In 305 older adults, 12 months of vitamin D supplementation substantially raised 25(OH)D but produced no significant improvement in hepcidin, ferritin, serum iron, transferrin, transferrin saturation or soluble transferrin receptor.
That null finding is developed with other trial evidence in Vitamin D Supplementation and Clinical Iron Markers Across Populations: Full Study.
Chronic kidney disease demonstrates why population matters
CKD changes several elements of the pathway simultaneously. Renal dysfunction alters active vitamin D physiology, erythropoietin, inflammation and hepcidin clearance. Randomized CKD studies therefore produce heterogeneous results, ranging from overall null effects to subgroup changes in haemoglobin or transferrin saturation.
Some dialysis studies report improvements in haemoglobin or reduced erythropoietin requirements without corresponding changes in ferritin, serum iron or transferrin saturation. Other trials show more complicated hepcidin trajectories. These findings make it unsafe to infer a universal iron benefit from one mechanistic biomarker.
Lower hepcidin is not always synonymous with better iron physiology
Hepcidin can fall because vitamin D suppresses its transcription, but it can also fall as an adaptive response to declining iron availability or increased erythropoietic demand. The direction of the hepcidin change therefore has to be interpreted alongside the rest of the iron system.
This is a central reason that apparently favourable biomarker movement should not automatically be translated into a clinical claim.
The three evidence layers answer different questions
The mechanistic evidence asks whether vitamin D can regulate HAMP and ferroportin. The inflammatory evidence asks how vitamin D, cytokines and hepcidin coexist during disease. The clinical-trial evidence asks whether supplementation changes the outcomes that matter further downstream, including transferrin saturation and haemoglobin.
All three are needed. Removing the mechanistic evidence would understate a real vitamin-D-regulated pathway. Removing the clinical null evidence would overstate its practical reach.
What the complete evidence supports
The evidence supports vitamin D as one regulator of iron homeostasis through the hepcidin-ferroportin axis. It supports interactions between vitamin D status, inflammation and anaemia-related iron restriction. It also supports substantial population variation in whether vitamin D supplementation changes clinical iron markers.
The evidence does not establish vitamin D supplementation as a universal treatment for iron deficiency or anaemia, does not justify interpreting ferritin without inflammatory context, and does not show that every reduction in hepcidin represents improved iron status.
The strongest physiology-first conclusion is therefore conditional: vitamin D can modify iron regulation, but the resulting whole-body effect depends on baseline vitamin D status, true iron stores, inflammation, kidney function, erythropoietic demand and the other constraints operating in the individual.
Scientific sources
Suppression of iron-regulatory hepcidin by vitamin D. PMID: 24204002.
High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. PMID: 27402475.
Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study. PMID: 30840757.
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial. PMID: 40452069.
The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease. PMID: 36698076.
Related reading
Effect of cholecalciferol on serum hepcidin and parameters of anaemia and CKD-MBD among haemodialysis patients: a randomized clinical trial
In this multicentre double-blind randomized clinical trial, we investigated the effects of oral cholecalciferol supplementation on serum hepcidin and parameters related to anaemia and CKD-MBD among haemodialysis patients.
Original paper ↗Read more →Etiology of Anemia in Older Mexican Adults: The Role of Hepcidin, Vitamin A and Vitamin D
The aim of this study is to analyze the etiology of anemia and anemia-related factors in older Mexican adults.
Original paper ↗Read more →Impact of vitamin D deficiency on iron status in children with type I diabetes
The current study aimed to elucidate the effect of VDD on iron status in children with type I diabetes mellitus (T1DM).
Original paper ↗Read more →Vitamin D Supplementation and Clinical Iron Markers Across Populations: Full Study
Randomized evidence showing why vitamin D supplementation has variable effects on hepcidin, ferritin, transferrin saturation and haemoglobin.
Read more →The Effect of Vitamin D Supplementation on Hepcidin, Iron Status, and Inflammation in Pregnant Women in the United Kingdom
Our aim was to identify whether antenatal vitamin D3 supplementation affects iron status (via hepcidin suppression) and/or inflammation.
Original paper ↗Read more →Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Full Study
Evidence linking vitamin D status with inflammation, hepcidin, iron restriction and haemoglobin in inflammatory disease.
Read more →Vitamin D, Inflammation and Anaemia-Related Iron Restriction: Study Summary
A concise review of vitamin D, inflammatory hepcidin signalling, iron restriction and anaemia-related physiology.
Read more →Alterations in regulators of the renal-bone axis, inflammation and iron status in older people with early renal impairment and the effect of vitamin D supplementation
Markers of the renal-bone axis, inflammation and iron status were investigated pre: and post-supplementation.
Original paper ↗Read more →Vitamin D Regulation of Hepcidin, Ferroportin and Iron Mobilisation: Full Study
Human and mechanistic evidence showing how vitamin D can suppress hepcidin, alter ferroportin regulation and influence iron mobilisation.
Read more →The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease
We evaluated the change in markers of hepcidin expression, erythropoiesis, and iron status from baseline to week 12 and compared the change between the groups.
Original paper ↗Read more →Vitamin D Supplementation and Clinical Iron Markers Across Populations: Study Summary
A concise review of why vitamin D supplementation produces variable effects on iron markers and haemoglobin across populations.
Read more →Serum Copper-to-Zinc Ratio and Oxidative Stress Are Associated with Anemia in Older Adults with Cardiovascular-Kidney-Metabolic Syndrome
We analyzed 2391 NHANES 2011 to 2016 participants ≥ 50 years of age with CKM stage I-IV.
Original paper ↗Read more →Epidemiology of 40 blood biomarkers of one-carbon metabolism, vitamin status, inflammation, and renal and endothelial function among cancer-free older adults
Imbalances of blood biomarkers are associated with disease, and biomarkers may also vary non-pathologically across population groups.
Original paper ↗Read more →Intact FGF23 and Markers of Iron Homeostasis, Inflammation, and Bone Mineral Metabolism in Acute Pediatric Infections
The aim of this prospective clinical study is to evaluate the association of i-FGF23 with hepcidin and markers of iron homeostasis, erythropoiesis, inflammation, and bone mineral metabolism in acute pediatric infections.
Original paper ↗Read more →Multiple Indicators of Undernutrition, Infection, and Inflammation in Lactating Women Are Associated with Maternal Iron Status and Infant Anthropometry in Panama: The MINDI Cohort
Maternal infections, nutrient deficiencies, and inflammation (MINDI) co-exist in lactating indigenous women in Panama, but their impact on maternal iron status and infant growth is unknown.
Original paper ↗Read more →Multiple Infections, Nutrient Deficiencies, and Inflammation as Determinants of Anemia and Iron Status during Pregnancy: The MINDI Cohort
In pregnant women with multiple infections, nutrient deficiencies, and inflammation (MINDI), the study of anemia and iron status is limited.
Original paper ↗Read more →Factors Contributing to Negative Outcomes Associated with Medications and Drug-Related Problems in Kidney Replacement Therapy: A Hospital-Based Prospective Observational Study
Background: Negative outcomes associated with medications (NOM) and drug-related problems (DRP) significantly impact individuals with kidney replacement therapy (KRT) given the complexities of managing kidney disease and associated comorbidities.
Original paper ↗Read more →Interactions between Serum Vitamin D Levels and Vitamin D Receptor Gene FokI Polymorphisms for Renal Function in Patients with Type 2 Diabetes
We aimed to examine associations among serum 25-hydroxyvitamin D (25OHD) levels, 1,25-dihyroxyvitamin D (1,25OHD) levels, vitamin D receptor (VDR) polymorphisms, and renal function based on estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes.
Original paper ↗Read more →The impact of a needs-oriented dental prophylaxis program on bacteremia after toothbrushing and systemic inflammation in children, adolescents, and young adults with chronic kidney disease
General prevalence of bacteremia after toothbrushing was 9.5% affecting 7 (26%) of the participants.
Original paper ↗Read more →Vitamin D Genetics Beyond Serum 25(OH)D: VDR rs2228570 (FokI) Polymorphism, Inflammation, and Quality of Life in Orthopedic Patients
This study investigated the rs2228570 (FokI) variant in relation to inflammatory, hematologic, and patient-reported outcomes in orthopedic patients.
Original paper ↗Read more →Vitamin D receptor polymorphisms and bone health after kidney transplantation
We investigated the relationship between the polymorphisms of the vitamin D receptor ( VDR ) gene and bone diseases occurring after kidney transplantation.
Original paper ↗Read more →Original sources
Suppression of iron-regulatory hepcidin by vitamin D
Suppression of iron-regulatory hepcidin by vitamin D.
Publication details
Suppression of iron-regulatory hepcidin by vitamin D. PMID: 24204002.
High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults
High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults.
Publication details
High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults. PMID: 27402475.
Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study
Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study.
Publication details
Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study. PMID: 30840757.
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial
The BEST-D trial, designed to establish the optimum dose of vitamin D3 for future trials, had 305 participants, aged 65 years or older, randomly allocated to 4000 IU vitamin D3 (n 102), 2000 IU vitamin D3 (n 102) or matching placebo (n 101).
Publication details
Effect of supplementation with vitamin D on biochemical markers of iron status and erythropoiesis in older people: BEST-D trial. PMID: 40452069.
The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease
We evaluated the change in markers of hepcidin expression, erythropoiesis, and iron status from baseline to week 12 and compared the change between the groups.
Publication details
The effect of high-dose vitamin D supplementation on hepcidin-25 and erythropoiesis in patients with chronic kidney disease. PMID: 36698076.